This class of medication is utilized to address symptoms related to physical discomfort, swelling, and fever. Keplat is primarily applied across domains where additional symptomatic support is needed, assisting in the management of pain and inflammation.

---

Relief from Key Symptoms and Conditions

Keplat is indicated for the management of symptoms related to physical discomfort such as headache, menstrual cramps, toothache, and muscle aches, and is commonly used in conditions characterized by periods of heightened symptoms. It also helps with symptoms associated with inflammatory or irritative states like swelling and stiffness from minor sprains, strains, or arthritis flare-ups, and is applied to manage fever. This support contributes to easing the overall symptom load and offers symptomatic relief that helps patients cope more steadily.

“It provides supportive relief when symptoms interfere with routine activities.”

---

Key Therapeutic Benefits

Relief from Pain and Inflammation is the central benefit. It is used in areas where short-term symptom management is appropriate, and is applicable within clinical settings that involve acute or disruptive symptom patterns. It is applied in scenarios where additional management of discomfort is required.

Quick Fact: Symptom Domains: Fever, Pain, and Swelling

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Keplat — Official Regulatory Information

The eligibility profile for Keplat (Ketoprofen transdermal patch) is officially defined by regulatory documents, establishing absolute prohibitions and specific conditions for use.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents aged 16 years and older.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Ketoprofen, any excipient, or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin.
	Patients with a history of NSAID-induced asthma attack, urticaria, or acute rhinitis.
	Third trimester of pregnancy (due to fetal risk).
Age-related eligibility rules	Use is contraindicated in those under 16 years of age as safety and efficacy have not been established. Older adults require caution.
Condition-specific eligibility rules	Use requires caution in patients with impaired renal, cardiac, or hepatic function, and those with a history of peptic ulcer or specific gastrointestinal conditions.
Pregnancy and lactation eligibility status	Third Trimester: Contraindicated. First/Second Trimester: Use is conditional and should only occur if clearly necessary. Lactation: Use with advice from a healthcare professional; the patch must not be applied to the breasts.
Eligibility-related restrictions	Must not be applied to pathological skin changes (e.g., eczema, wounds). Treated skin must be protected from sun/UV light during treatment and for two weeks after discontinuation.

Connection to the overall eligibility profile

Regulatory documents establish absolute prohibitions for patients with hypersensitivity or late-stage pregnancy, classifying these as contraindicated. The framework mandates conditional use (Use with Caution) for vulnerable groups like the elderly or those with impaired organ function, strictly limiting use to the approved adult and older adolescent population who meet all non-eligibility criteria.

Interactions with other medicines and products

Keplat is a medicinal product containing ketoprofen, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Like all NSAIDs, ketoprofen has a known profile of potential interactions with other medicinal products, primarily due to effects on prostaglandin synthesis, platelet function, and, for oral forms, drug metabolism and kidney function. While Keplat is a localized product (such as a medicated plaster) and the systemic absorption of ketoprofen is generally low, the risk of systemic interactions cannot be entirely excluded, especially with prolonged use or co-administration of highly interacting drugs.

Key interacting product categories, based on the established profile of oral ketoprofen and the NSAID class, include:

• Other NSAIDs, Salicylates, and Corticosteroids: Concomitant use with other NSAIDs (including aspirin) is generally not recommended due to a synergistic risk of serious gastrointestinal side effects, such as bleeding and ulceration.
• Anticoagulants and Antiplatelet Agents: Combining with medicines like warfarin, heparin, or other antiplatelet drugs increases the risk of bleeding due to combined effects on blood clotting mechanisms.
• Diuretics and Antihypertensives: NSAIDs can reduce the therapeutic effectiveness of blood pressure medications, including ACE inhibitors and diuretics, and may increase the risk of kidney function impairment in susceptible patients.
• Lithium and Methotrexate: NSAIDs can lead to elevated plasma levels of both lithium and methotrexate by affecting their renal clearance, thereby increasing the risk of toxicity from these medications. Close monitoring of blood levels is necessary if used concomitantly.

Patients should provide a complete list of all medications, including over-the-counter products, supplements, and herbal remedies, to their healthcare professional to assess the individual risk of interaction.

Molecular Inhibition of Prostaglandin Synthesis

The active ingredient, Ketoprofen, functions as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically the COX-1 and COX-2 isoforms. This primary action blocks the enzymatic conversion of arachidonic acid into prostaglandins—signaling mediators that participate in inflammatory and nociceptive pathways. This mechanism modulates pathways associated with the production of local inflammatory mediators.

---

Localized Modification of Peripheral Signaling

The transdermal patch design facilitates the local accumulation of Ketoprofen in the subcutaneous tissue, ensuring the inhibitory effect is primarily located peripherally. This inhibition of prostaglandin production produces a dual physiological effect: it attenuates local prostaglandin-mediated vascular responses and lowers the hyper-sensitization of peripheral nociceptors. This targeted pathway adjustment results in a local modification of inflammatory and nociceptive signaling.

---

️ Mechanistic Constraints

The topical delivery intrinsically limits the mechanism's physiological influence to superficial structures. The drug's mechanism is physiologically constrained in deep-seated or systemic processes that necessitate widespread modulation across central pathways.

The administration of the Ketoprofen medicated plaster (Keplat) focuses on precise topical use and scheduling. The content explains the procedural structure for administration.

Administration Route and Scheduling

Keplat is designated for topical administration, which involves the application of the medicated plaster directly to the intact skin. This approach is the only route for this specific product form. The standard regimen involves applying one plaster to the affected localized area. Depending on the strength, such as the 30 mg sheet, the frequency is typically scheduled for once or twice daily application. The use of this medicine is defined as a short-term course, with a maximum duration of 14 days for acute, localized use.

Procedural Requirements and Handling

Specific conditions must be met prior to and during application to ensure proper use. The skin site must be clean, dry, and non-hairy before the plaster is applied. The plaster should be placed on the skin immediately after removal from its protective packaging. Administration requires that the plaster not be cut and that occlusive bandages are restricted from use over the application site. For scheduling, if an application is missed, a double application must not be used to compensate. There are generally no specific numerical dose adjustments for the topical form in older adults or those with mild organ impairment.

Connection to the Overall Use Protocol

These instructions establish an external-use protocol for the medicine, defining the required environment, application frequency, and maximum duration necessary to adhere to the administration criteria. This clear framework governs the procedural structure for using the topical plaster.

Research Evidence / Overview of Studies for Keplat

Overview of Studies for Localized Acute Pain

Research exploring topical ketoprofen, the active ingredient in the Keplat patch, was studied for conditions involving short-term and acute symptoms, such as minor sprains, strains, and localized inflammation like tendonitis. The primary evidence source for this context comes from short-term randomized controlled trials (RCTs) and subsequent systematic reviews. These studies examined adult populations with acute episodes, monitoring responses over defined time intervals, typically lasting one to two weeks.

In these trials, the studies monitored how symptoms evolved in the observed populations, comparing the medicated formulation against a non-medicated placebo patch or carrier. Findings describe the measurements of pain intensity and outcomes reflecting daily functioning observed in the studies. Due to the limited follow-up durations, the research does not establish how long the measured changes persist after the treatment period ends.

---

Research in Chronic Musculoskeletal Conditions (Osteoarthritis)

Research has also explored chronic musculoskeletal pain, which is characterized by functional limitations, particularly when associated with small-joint osteoarthritis, most commonly the knee. Research for this use involved medium-term randomized controlled trials, with studies observing responses over time intervals usually lasting between six and twelve weeks.

Studies describe the measurements obtained during the study period for these long-standing conditions. Systematic data show patterns related to modest measurements recorded compared to baseline. Findings indicate that observed measurements in pain scores for these chronic conditions differed from those measured in acute injury trials, and the evidence is limited primarily to knee and hand joint issues.

---

Areas of Uncertainty and Research Gaps

Evidence in special populations is limited; published information on outcomes in pediatric populations (children and adolescents) is insufficient. Comparative evidence is also lacking regarding the relative performance of the Keplat plaster specifically against other topical forms of the same active ingredient. There is limited information for long-term outcomes, and research describing effects in large, deep joints (such as the hip or shoulder) is minimal. Overall, the research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References Ketoprofen (Topical) Drug Information and Clinical Studies Overview (FDA/NIH Monograph)

Common questions about Keplat (FAQ)

Q: How is Keplat different from other medicines used for the same condition?

The medicated plaster formulation is designed to allow for the local accumulation of the drug in the tissue at the application site. According to official information, this approach results in low systemic absorption—meaning less of the drug enters the bloodstream—compared to taking oral forms of the medicine for the same active ingredient.

Q: Are the side effects of Keplat typically mild and temporary?

Official safety documents classify adverse reactions by frequency (e.g., uncommon, rare, very rare). The most commonly documented reactions are localized skin issues, such as itching or a burning sensation, at the application site. However, the label also includes information on rare but serious systemic effects related to the NSAID drug class, which is why precautions are formally outlined.

Q: Is it true that Keplat has a risk of causing stomach upset or GI issues?

Since the active ingredient is an NSAID, the label advises caution for individuals who have a history of conditions like a peptic ulcer. While the patch is applied topically, official documents confirm that the systemic risks associated with the NSAID class are formally noted, and therefore the precaution remains relevant.

Q: Does Keplat have known interactions with common herbal supplements?

The official interaction profile does not list specific common herbal interactions. However, the official profile notes the importance of a healthcare professional assessing all medicines, supplements, and herbal remedies to evaluate the individual risk of interaction.

Q: How quickly does Keplat usually start to show an effect?

Clinical studies monitoring patient response for localized pain typically assess symptom evolution over a defined period of time. Evidence for this type of medication often observes measured changes in pain intensity over intervals like one or two weeks.

Q: Are there any special warnings about driving or operating machinery while on Keplat?

Official safety information notes that the medicine may cause effects such as dizziness or drowsiness. The product label indicates that activities requiring mental alertness, such as driving or using machinery, should be avoided until one can safely confirm they are unaffected.

Q: Is Keplat a medicine that requires a prescription?

Keplat is listed in official national drug formularies. Due to the drug class and specific formulation, it is typically classified as a prescription-only medicine in many regulated territories.

Q: What are the official recommendations about consuming alcohol while taking Keplat?

Regulatory documents advise that consuming alcohol while using medicines containing the active ingredient (Ketoprofen) can increase the risk of gastrointestinal bleeding. The documented increase in risk is the basis for regulatory information stating the combination should generally be avoided.

Q: Can Keplat cause changes in a person's mood or energy levels?

The full safety profile for the active ingredient notes that, while uncommon for the topical form, effects on the nervous system may include symptoms such as drowsiness, difficulty falling asleep, nervousness, or dizziness.

Q: Does Keplat affect the absorption or action of birth control pills?

While specific interaction data for the topical patch is limited, NSAIDs as a drug class have been observed in studies to potentially increase the risk of venous thromboembolism (VTE) (a type of blood clot) when combined with combined hormonal contraceptives.

Q: What is the general expectation for how long the effects of Keplat last?

Official administration guidelines state that the medicated plaster is typically intended for application once every 12 hours.

Q: Is it common to experience minor headaches when first starting Keplat?

The overall safety profile for the active ingredient includes headache as a possible nervous system side effect. However, the most common adverse effects documented for the topical patch are primarily localized skin reactions at the application site, not typically headaches.

Q: What should be considered if Keplat seems to stop working over time?

Official administration guidance notes that if there is no improvement in pain, or if symptoms worsen after a set period of treatment (e.g., 7 days), regulatory information indicates a healthcare professional should be consulted.

Q: Is Keplat known to interact with common diabetes medications?

The active ingredient belongs to a drug class that has documented interactions with certain diabetes medications (e.g., Metformin). The official interaction profile notes that this combination could potentially increase the risk of side effects like lactic acidosis.

The official storage and disposal instructions for Keplat (Ketoprofen Medicated Plaster) are defined by regulatory standards to maintain stability and ensure safety.

Storage Requirements

The product must be stored below 25 C or a maximum of 30 C and not refrigerated or frozen. Store the medicated plaster in its original package to ensure protection from light and moisture. Always keep the product out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Keplat through household waste or wastewater. The unused product must be discarded according to local regulations for pharmaceutical waste to prevent environmental contamination and accidental exposure.